MedTrace Logo

18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy

NCT05479136 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-10-27

No results posted yet for this study

Summary

This study will examine whether positron emission tomography (PET) imaging with fluciclovine can reliably differentiate true progression from pseudoprogression months earlier than the conventional MRI methods.

Conditions

  • Grade III or Grade IV Glioma

Interventions

DRUG

PET imaging with 18F fluciclovine

PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus

Sponsors & Collaborators

  • Blue Earth Diagnostics

    collaborator INDUSTRY

  • Barrow Neurological Foundation

    collaborator OTHER

  • Nicole Hill

    lead OTHER

Principal Investigators

  • Poonam Choudhary, PhD · Barrow Neurological Institute

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-24
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05479136 on ClinicalTrials.gov